Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells

Hepatocellular carcinoma (HCC) is one of the common malignancies and is an increasingly important cause of cancer death worldwide. Surgery, chemotherapy, and radiation therapy extend the 5-year survival limit in HCC patients by only 6%. Therefore, there is a need to develop new therapeutic approache...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Death Dis
Hlavní autoři: Augello, Giuseppa, Modica, Martina, Azzolina, Antonina, Puleio, Roberto, Cassata, Giovanni, Emma, Maria Rita, Di Sano, Caterina, Cusimano, Antonella, Montalto, Giuseppe, Cervello, Melchiorre
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833482/
https://ncbi.nlm.nih.gov/pubmed/29348495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-017-0195-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky